Atezolizumab-Induced Stevens-Johnson Syndrome in a Patient with Non-Small Cell Lung Carcinoma

被引：30

作者：

Chirasuthat, Phatcharawat ^{[1
]}

Chayavichitsilp, Pamela ^{[1
]}

机构：

[1] Mahidol Univ, Ramathibodi Hosp, Div Dermatol, Bangkok, Thailand

来源：

CASE REPORTS IN DERMATOLOGY | 2018年 / 10卷 / 02期

关键词：

Drug eruption; Drug hypersensitivity syndrome; Stevens-Johnson syndrome; Lung cancer; Lung cancer treatment; Cancer;

D O I：

10.1159/000492172

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Atezolizumab is a humanized anti-PD-L1 immune checkpoint antibody that is currently used in many kinds of advanced carcinoma including metastatic non-small cell lung cancer. The cutaneous side effect profile reported only 20% of the patients which had only mild maculopapular rash that required no treatment. There is no case report of anti-PD-L1 antibody-induced Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN) eruptions. To the best of our knowledge, there is no case report of atezolizumab-induced SJS or SJS/TEN induced by anti-PD-L1 immune checkpoint antibodies. We believe that our report will be useful to dermatologists who are consultants in the inpatient settings, as atezolizumab is an antineoplastic agent that has a potential to be used in multiple malignancies. (c) 2018 The Author(s) Published by S. Karger

引用

页码：198 / 202

页数：5

共 10 条

[1] Cytotoxic Cutaneous Adverse Drug Reactions during Anti-PD-1 Therapy [J].

Goldinger, Simone M. ;

Stieger, Pascale ;

Meier, Barbara ;

Micaletto, Sara ;

Contassot, Emmanuel ;

French, Lars E. ;

Dummer, Reinhard .

CLINICAL CANCER RESEARCH, 2016, 22 (16) :4023-4029

[2] Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma [J].

Liniker, E. ;

Menzies, A. M. ;

Kong, B. Y. ;

Cooper, A. ;

Ramanujam, S. ;

Lo, S. ;

Kefford, R. F. ;

Fogarty, G. B. ;

Guminski, A. ;

Wang, T. W. ;

Carlino, M. S. ;

Hong, A. ;

Long, G. V. .

ONCOIMMUNOLOGY, 2016, 5 (09)

[3] Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study [J].

McDermott, David F. ;

Sosman, Jeffrey A. ;

Sznol, Mario ;

Massard, Christophe ;

Gordon, Michael S. ;

Hamid, Omid ;

Powderly, John D. ;

Infante, Jeffrey R. ;

Fasso, Marcella ;

Wang, Yan V. ;

Zou, Wei ;

Hegde, Priti S. ;

Fine, Gregg D. ;

Powles, Thomas .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (08) :833-+

[4] Toxic Epidermal Necrolysis-like Reaction With Severe Satellite Cell Necrosis Associated With Nivolumab in a Patient With Ipilimumab Refractory Metastatic Melanoma [J].

Nayar, Namrata ;

Briscoe, Karen ;

Penas, Pablo Fernandez .

JOURNAL OF IMMUNOTHERAPY, 2016, 39 (03) :149-152

[5] Programmed cell death 1 (PD-1) regulates the effector function of CD8 T cells via PD-L1 expressed on target keratinocytes [J].

Okiyama, Naoko ;

Katz, Stephen I. .

JOURNAL OF AUTOIMMUNITY, 2014, 53 :1-9

[6] Pembrolizumab-induced Stevens-Johnson syndrome in non-melanoma patients [J].

Saw, Stephanie ;

Lee, Haur Yueh ;

Ng, Quan Sing .

EUROPEAN JOURNAL OF CANCER, 2017, 81 :237-239

[7] Clinical and Histologic Features of Lichenoid Mucocutaneous Eruptions Due to Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Immunotherapy [J].

Shi, Veronica J. ;

Rodic, Nemanja ;

Gettinger, Scott ;

Leventhal, Jonathan S. ;

Neckman, Julia P. ;

Girardi, Michael ;

Bosenberg, Marcus ;

Choi, Jennifer N. .

JAMA DERMATOLOGY, 2016, 152 (10) :1128-1136

[8] Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies [J].

Sibaud, Vincent ;

Meyer, Nicolas ;

Lamant, Laurence ;

Vigarios, Emmanuelle ;

Mazieres, Julien ;

Delord, Jean Pierre .

CURRENT OPINION IN ONCOLOGY, 2016, 28 (04) :254-263

[9] Epidermal programmed cell death-ligand 1 expression in TEN associated with nivolumab therapy [J].

Vivar, Karina L. ;

Deschaine, Maria ;

Messina, Jane ;

Divine, Jennifer M. ;

Rabionet, Alejandro ;

Patel, Nishit ;

Harrington, Michael A. ;

Seminario-Vidal, Lucia .

JOURNAL OF CUTANEOUS PATHOLOGY, 2017, 44 (04) :381-384

[10] Systemic Immunomodulating Therapies for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis A Systematic Review and Meta-analysis [J].

Zimmermann, Stefanie ;

Sekula, Peggy ;

Venhoff, Moritz ;

Motschall, Edith ;

Knaus, Jochen ;

Schumacher, Martin ;

Mockenhaupt, Maja .

JAMA DERMATOLOGY, 2017, 153 (06) :514-522

← 1 →